Toshiba commercial agreement
February 13 2008 - 2:02AM
UK Regulatory
RNS Number:8809N
Medicsight Plc
13 February 2008
Press Release 13 February 2008
Medicsight PLC
("Medicsight" or "the Company")
Medicsight and Toshiba PACS division sign commercial agreement
Medicsight PLC (AIM:MDST) is pleased to announce that it has signed a
preliminary agreement with the System Integration division of Toshiba Medical
Systems Corporation ("Toshiba") for the resale of its MedicRead Colon and
ColonCAD software solutions throughout Japan.
Toshiba Medical Systems Corp. is a global leading provider of diagnostic medical
imaging systems and comprehensive medical solutions, such as CT, X-ray,
Ultrasound, Nuclear Medicine, MRI and information systems. Toshiba will work
with Medicsight to obtain MHLW approval in Japan. In addition, both companies
have also identified the need for radiologists and gastroenterologists to be
trained in the use of the software to help them to interpret CT colonography
(CTC) images and rapidly identify suspicious regions for detailed evaluation. In
late October Medicsight and Toshiba hosted CTC training workshops at the
Japanese Digestive Disease Week (JDDW) conference in Kobe. The JDDW conference
is the largest Gastroenterological congress of the year in Japan. Medicsight and
Toshiba will continue to work together on similar market development initiatives
in 2008 and beyond.
David Sumner, Chief Executive of Medicsight, commented: "We are delighted to be
working with Toshiba, one of the worlds largest medical imaging solution
providers. This agreement is timely as the recently announced positive outcomes
of two major clinical trials are widely expected to accelerate the adoption of
CTC (also known as virtual colonoscopy) as routine primary screening for
colorectal cancer. Toshiba will help to promote the use of our MedicRead Colon
and ColonCADTM software to ease the workload of radiologists and to help them
accurately identify colorectal polyps and tumours at an early stage when there
is a good chance of successful treatment. We see this as bringing important
benefits to both Japanese patients and the Japanese healthcare system alike."
Takashi Masuzawa, Chief Specialist of Toshiba System Integration development
department, added: "We believe that the Medicsight advanced software solutions
will augment the strong portfolio of Toshiba products and provide an opportunity
to market the integrated PACS products to current and future customers. Both
Medicsight and Toshiba view this agreement as the start of a long term
relationship for CT colonography solution in Japan. It is the intent of this
agreement to continue further development and licensing of joint Medicsight and
Toshiba products through the Toshiba PACS channel."
Gen Iinuma, Head of Staffs, Diagnostic Radiology Division, National Cancer
Center Hospital Tokyo, commented: "We have been working on the development of
the Medicsight ColonCAD in collaboration with Professor Steve Halligan,
University College Hospital, for some time now. This collaboration consists of a
3 year clinical programme, which when delivered upon will deliver 8 clinical
studies to support both the regulatory and sales & marketing efforts of
Medicsight and Toshiba. We have been delighted with the performance of the
product and are very pleased that the Radiology community at large will soon
have this additional software solution available to them to help combat this
debilitating and potentially fatal disease."
- ENDS -
For further information:
Medicsight PLC
David Sumner Tel: +44 (0)20 7605 7950
www.medicsight.com
Collins Stewart Europe Limited
Tim Mickley Tel: +44 (0)20 7523 8350
Jonny Sloan Tel: +44 (0)20 7523 8302
Media enquiries:
Abchurch
Ashley Tapp Tel: +44 (0) 20 7398 7711
Mobile: +44 (0) 7944 570 387
ashley.tapp@abchurch-group.com
Stephanie Cuthbert Tel: +44 (0) 20 7398 7718
Mobile: +44 (0) 7843 080 947
stephanie.cuthbert@abchurch-group.com www.abchurch-group.com
Notes to editors
Medicsight PLC is a UK-based, research driven, leading developer of
computer-aided detection (CAD) and image analysis software for the medical
imaging market. The CAD software automatically highlights suspicious areas on
computerised tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early indicators of
disease. Medicsight's computer-aided detection (CAD) software has been validated
using one of the world's largest and most population diverse databases of
verified patient CT scan data. Medicsight's ColonCADTM and LungCADTM software
products are seamlessly integrated with the advanced 3D visualisation
workstations of several industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 1000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This is critical
for diagnosis and the management of patient outcomes as early detection of
disease greatly increases the probability of successful treatment and a positive
therapeutic outcome.
About Medicsight's CAD software
Medicsight's ColonCADTM and LungCADTM software use an advanced CAD algorithm to
analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.
Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.
About ACRIN 6664
The preliminary results of the National US Computerised Tomography (CT)
Colonography Trial (ACRIN study 6664), released on 28 September, demonstrated
convincingly that CT colonography is at least as sensitive and specific as
conventional optical colonoscopy in detecting adenomas of 1 cm diameter or
larger. A few days later another major study(1) was published in the prestigious
New England Journal of Medicine with a similar outcome. These compelling results
from two large well-controlled studies are expected to lead to widespread
adoption of CT colonography (also known as virtual colonoscopy) as routine
primary screening for colorectal cancer.
--------------------------
(1) Kim et al., "CT Colonography versus Colonoscopy for the Detection of
Advanced Neoplasia", NEJM 357, 1403-1412 (4 October 2007)
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFKNKQABKKPBD
Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024
